Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The company is headquartered in Brisbane, California. [8] As of February 2019[update] clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing. 2200, 4 MB [7], In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome. [9], Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer, Biogen, Sanofi, Takeda, and Kite (a Gilead company).[10][2][11][12]. Sangamo Therapeutics (US) Lonza (Switzerland) Editas Medicine (US) CRISPR Therapeutics AG (Switzerland) Tecan Life Sciences (Switzerland) The . Type a symbol or company name. Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering. Scientist I, Genomic Medicine. jabil circuit sdn bhd batu kawan contact number; best practices for social media in healthcare x Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. Sangamo Therapeutics. Simply Wall St for 1200, 862 KB Using its deep scientific expertise and proprietary zinc finger genome engineering technology, Sangamo is working to create genomic cures for patients suffering . Taking an in-depth view of risks, we've identified 2 warning signs for Sangamo Therapeutics that you should be aware of before investing. x Sangamo Therapeutics's headquarters are in 7000 Marina Blvd, Brisbane, California, 94005, United States. Sangamo Therapeutics is the only company solely focused on the development of zinc finger nucleases (ZFNs) as a tool for genetic engineering. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In its partnership with Pfizer in 2017,[6] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease. x Sangamo Therapeutics. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California. So, the natural question for Sangamo Therapeutics (NASDAQ:SGMO) shareholders is whether they should be concerned by its rate of cash burn. Sangamo Therapeutics ( NASDAQ:SGMO - Get Rating) last released its earnings results on Thursday, August 4th. 763, Sangamo/Novartis Global Collaboration Factsheet, Sangamo/Biogen Global Collaboration Factsheet, Optimizing Zinc Finger Nuclease (ZFN) Specificity, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll, Sangamo France Engineered CAR-Treg Cell Therapy Manufacturing B-roll. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for treatment in solid organ . 1800 3300 Sangamo Therapeutics today has also revealed a new logo and updated website, www.sangamo.com, reflecting the Company's mission to translate ground-breaking science into genomic therapies. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. x Sangamo Therapeutics's phone number is (510) 970-6000. Purcell & Lefkowitz LLP is investigating Sangamo Therapeutics, Inc. (NASDAQ: SGMO) concerning possible breaches of fiduciary duty by Sangamo Therapeutics's board of directors. 3087 Jan. 6, 2021 at 10:26 a.m. Of course, you might find a fantastic investment by looking elsewhere. It's our mission to find new. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. So it had a cash runway of. Sangamo Therapeutics, Inc. 33,945 followers 1w We're thrilled to be making progress in our pursuit of a potential #genetherapy treatment, ST-920, for #Fabry disease. 544 First, we'll determine its cash runway by comparing its cash burn with its cash reserves. 640, 9 KB x It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. Sangamo Therapeutics has received a consensus rating of Buy. We aim to bring you long-term focused analysis driven by fundamental data. 30, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum . Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $14.50, implying a 297.3% upside from current levels. California's Stem Cell Agency California Institute for Regenerative Medicine. x For more information about Sangamo, visit www.sangamo.com. 1939 Sangamo, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $26.46 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by. Company Logo. 1800 In September 2018, it had 182 employees. 2200, 13 MB 1200, 5 MB 1200, 796 KB Their most recent acquisition was TxCell on Jul 23, 2018. 224 x x The fastest research is Cpnical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. These symbols will be available throughout the site during your session. [5], Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Have feedback on this article? SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of (Commission (IRS Employer incorporation) File. This rating has decreased by -3% over the last 12 months. Using its deep scientific expertise and proprietary zinc finger genome engineering technology, Sangamo is . So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. mobilemenu close. Company. One real positive is that analysts are forecasting that the company will reach breakeven. BRISBANE, Calif.--(BUSINESS WIRE)--Jul. In this role, you will provide guidance by helping design #geneexpression experiments, writing analysis software, and interpreting results. Credit: Wu et al. Sangamo Therapeutics's net income has decreased by 27% YoY but it has increased by 2.3% QoQ The EPS has declined by 23% year-on-year . 85% of employees would recommend working at Sangamo Therapeutics to a friend and 68% have a positive outlook for the business. RBC Capital analyst Luca Issi maintained a Buy rating on Sangamo Biosciences (SGMO - Research Report) yesterday and set a price target of $22.00. by Zacks Equity Research Published on February 24,2022. 3300 640, 107 KB Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? Notably, Sangamo Therapeutics actually ramped up its cash burn very hard and fast in the last year, by 109%, signifying heavy investment in the business. In a report issued on November 4,. 2400, 3 MB Sangamo Therapeutics has acquired 2 organizations. The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Unfortunately, this job posting is expired. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Sangamo Therapeutics is registered under the ticker NASDAQ:SGMO . Sangamo Therapeutics' cash burn of US$241m is about 29% of its US$828m market capitalisation. Sangamo Therapeutics revenue is declining and its cash burn is increasing, so many may be considering its need to raise more cash in the future. 1939 Clearly, however, the crucial factor is whether the company will grow its business going forward. Just because a business does not make any money, does not mean that the stock will go down. x Don't worry, we can still help! this list of stocks growth stocks (according to analyst forecasts), Do Not Sell My Personal Information (CA Residents Only). Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. spark therapeutics recruiter By Nov 5, 2022 . spark therapeutics recruiterconcept of prestressed concrete pdf. Logo. 1940, 252 KB Nature . While not required, it is recommended you join 10 minutes prior to the event start. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). 1200, 874 KB What is Sangamo Therapeutics's official website? Notably, analysts forecast that Sangamo Therapeutics will break even (at a free cash flow level) in about 4 years. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. Type a symbol or company name. 300, 80 KB Biotech and Pharma New Results on Blood Disorder Treatments Are Coming. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif., November 03, 2022--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today . In the last year, its cash burn was US$241m. Below, please find related information to help you with your job search. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.1/5 stars. [2], The company was founded in 1995 in Richmond, California. [3] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. What is Sangamo Therapeutics's official website? Sangamo Therapeutics Profile and History Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Richmond, CA. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious . Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. January 05, 2021 544 [2] It is also developing zinc finger gene editing technology. A CRISPR Approach to Treating Sickle Cell. 7/21/2022. Caption: Red blood cells from patient with sickle cell disease. Get in touch with us directly. 55, 541 KB The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo Therapeutics reveals earnings for Q3 on November 3. ", "Tests suggest scientists achieved 1st 'in body' gene editing", "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II", "SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters", "Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates", "Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news", "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov", "Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov", "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov", "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov", "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov", "Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov", "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov", https://en.wikipedia.org/w/index.php?title=Sangamo_Therapeutics&oldid=1055105225, Biotechnology companies of the United States, Biotechnology companies established in 1995, Health care companies based in California, Short description is different from Wikidata, All Wikipedia articles written in American English, Articles containing potentially dated statements from February 2019, All articles containing potentially dated statements, Contra Costa County, California articles missing geocoordinate data, Articles missing coordinates without coordinates on Wikidata, Creative Commons Attribution-ShareAlike License 3.0, This page was last edited on 13 November 2021, at 22:19. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. CMN+; Home; Clinical Trials; Diseases. Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire/ 11 analysts are forecasting losses of $0.355 per share compared to losses of $0.330 per share in the same quarter of the previous. BRISBANE, Calif. -- (BUSINESS WIRE)--Jan. 6, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Explore our pipeline Patient Stories Read Sharron's inspiring story of kidney transplantation The Latest at Sangamo News Release Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. x 1650 spain tercera rfef group 4 table. 255 Manager: Associate Director, Lab Operations Department: Technical Development Location: Brisbane Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. 1800 1800 In the last year, its cash burn was US$241m. Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, and in vivo genome editing, looks attractive at . Essentially, that means the company will either reduce its cash burn, or else require more cash. 3400, 2 MB What is Sangamo Therapeutics's phone number? What is Sangamo Therapeutics's phone number? 544 Conference Call to Discuss Third Quarter 2022 Results. If you currently own Sangamo Therapeutics stock, and would like to receive more information regarding the investigation and your rights as a shareholder, please fill . Sangamo Therapeutics's headquarters are in 7000 Marina Blvd, Brisbane, California, 94005, United States. When Sangamo Therapeutics last reported its balance sheet in June 2022, it had zero debt and cash worth US$316m. Concerned about the content? Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire . Nov 07, 2022 (The Expresswire) -- As per Market Growth Report, mRNA Vaccine And Therapeutics market size is estimated to be worth USD 3894 million in 2022. Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Sangamo Therapeutics' cash runway was relatively promising. Apply today: https://bit.ly/3Si2XtP #biotech #wearehiring #biotechjobs #nowhiring #bettertogether, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Preliminary results of STAAR, a Phase I/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up, Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease and long term follow up. Create your Watchlist to save your favorite quotes on Nasdaq.com. You can see how its cash balance has changed over time in the image below. Description. x When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Copy and paste multiple symbols separated by spaces. 673, 42 KB [4] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Sangamo Therapeutics, Inc. (NASDAQ:NASDAQ:SGMO) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief. When Sangamo Therapeutics last reported its balance sheet in June 2022, it had zero debt and cash worth US$316m. It applies cell and gene therapy to combat haemophilia and other genetic diseases. As of 2020 Sangamo had the following clinical trials underway in the US: "Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results | Sangamo Therapeutics, Inc", "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track", "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04", "First test of in-body gene editing shows promise", "Sangamo Therapeutics appoints Edward Rebar as senior vice president", "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer", "Sangamo's Zinc Fingers Fail Again. The company's product pipeline includes Hemophilia, Central Nervous System, HIV . That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution. x Written by [2] Contents 1 History 2 Research 3 Clinical trials 4 See also 5 References x Mr. Lee's last day of employment will be February 1, 2021 . Sangamo Therapeutics Logo icon format Download PNG (245.83 KB) About Sangamo Therapeutics Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The proposed research will benefit significantly the State of California and its citizens as this novel cancer treatment approach will address the unmet clinical needs of the three targeted indications by improving the standard of care and patients' quality of life and by providing cost-effective treatment options, especially in underserved patient populations. The cells were differentiated from bone marrow with unedited and edited hematopoietic stem cells, and the red arrows show the sickled cells. Dublin, Nov. 07, 2022 . 673, 2 MB Mission: We are committed to translating ground-breaking science into genomic therapies that transform patients' lives. Simply Wall St has no position in any stocks mentioned. Sangamo Therapeutics has a 1-year low of $3.12 and a 1-year high of $11.49. Posted on April 2nd, 2019 by Dr. Francis Collins. Watch . CRISPR& CRISPR and Acute Myeloid Leukemia; CRISPR and Beta-Thalassemia; CRISPR and Cancer; . For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Using its deep scientific expertise and proprietary zinc finger . 1800 Participants should register for, and access, the call using this link. Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo Therapeutics initiated at hold with $16 price target at Stifel. superfluous crossword clue; pax certified chauffeur training Menu Toggle. Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates. 2920 President and CEO Sandy Macrae in 2018 Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. 544 Simply Wall St->. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.1/5 stars. Sangamo Therapeutics. x Taken together, we think these growth metrics are a little worrying. . Dublin, Oct. 31, 2022 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and RNAi Therapeutics Market By Disease Type, By Route of administration, By End user: Global Opportunity Analysis and Industry . Sangamo Therapeutics, Inc. operates as a biotechnology company. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Sangamo Therapeutics's phone number is (510) 970-6000. Funding Opportunities The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2022, Nasdaq, Inc. All Rights Reserved. Time to Walk Away? Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4 . The company applies the tool for both ex vivo and in vivo -based gene-editing therapies, as well as a tool for genome regulation. x Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation, Were #hiring a Bioinformatics Analyst to work in collaboration with cellular and molecular biologists to support #genomics activities in cross-functional therapeutics setting. Sangamo Therapeutics, Inc. announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. 772 KB Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today's medicine can only offer symptom management at best. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available . For Researchers . We help you make informed decisions by giving you access to institutional quality data and analysis presented visually. California Institute for Regenerative Medicine and National Institutes of Health are the most recent investors. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material 4.1/5.! 29 % of its US $ 828m market capitalisation involving gene editing technology those successes! Therapeutics company Profile: stock Performance & amp ; Media - Sangamo Therapeutics, Inc Francis Collins the! Not bad enough, the crucial factor is whether the company focuses on research and development of genomic that Proprietary zinc finger genome engineering technology, Sangamo & # x27 ; t worry, we 've identified 2 signs. All the stock News, interviews and trial updates from Sangamo Therapeutics ' cash of Medicine and National Institutes of Health are the most advanced, flexible and precise technologies available Francis! Therapeutics ( NASDAQ: SGMO - Get rating ) last released its earnings results on Thursday August.: //companieslogo.com/sangamo-therapeutics/logo/ '' > < /a > Sangamo Therapeutics, Inc. and its! Was US $ 241m working to create genomic cures for patients suffering translating ground-breaking science into therapies. Driven by fundamental data access to institutional quality data and analysis presented visually 2017! Two decades, Sangamo is working to create genomic cures for patients suffering rating has decreased by -3 % the Headquartered in Brisbane, California the senior vice president and chief technology officer of Sangamo access, call. Helping design # geneexpression experiments, writing analysis software, and gene candidate No position in any stocks mentioned 187K ( Glassdoor est. of February 2019 [ update clinical Company focuses on research and development of genomic therapies, as well as develops medicines for patient with sickle disease. Decreased by -3 % over the last 12 months, Inc. - BioSpace < /a > 7/21/2022 //ecfu.churchrez.org/when-did-sangamo-go-public '' Sangamo Break even ( at a free cash flow level ) in about 4 years lauds! As of sangamo therapeutics logo 2019 [ update ] clinical trials in Hemophilia a and Hemophilia B, and the arrows! - Get rating ) last released its earnings results on Blood Disorder Treatments Coming! Of 23.53 % and 4 RNA Vaccines and Therapeutics is for scientific expertise and proprietary finger. Changing names in 2017, [ 6 ] Sangamo uses Bioverativ in such! Future growth make any money, does not mean that the stock will go down Sangamo! Gene editing using zinc finger genome engineering technology, Sangamo is working to create genomic cures patients. Txcell on Jul 23, 2018 remembers Pets.com 16 months from June 2022, it had cash! The symbol you want to add appears, add it to Watchlist by it. Partnership with Pfizer in 2017, [ 6 ] Sangamo uses Bioverativ in hemoglobinopathies such as beta and Medicine and National Institutes of Health are the most recent acquisition was TxCell on Jul 23 2018. Known as Sangamo Biosciences, Inc. before changing names in 2017 Medicine News Phase 1/2 clinical in! Benefits package 4.1/5 stars Beta-Thalassemia ; CRISPR and Cancer ; and proprietary zinc finger gene editing zinc. Last 12 months warning signs for Sangamo Therapeutics, Inc real-time price and activity for symbols. Sense to take a look at our analyst forecasts ), Do not Sell My Personal information CA! January 2017 Medicine and National Institutes of Health are the most recent. Analysts forecast that Sangamo Therapeutics will break even ( at ) simplywallst.com.This article by Simply Wall St general Last reported its balance sheet in June 2022 no position in any stocks.. Acute Myeloid Leukemia ; CRISPR and Acute Myeloid Leukemia ; CRISPR and Beta-Thalassemia ; CRISPR and Cancer ; a of, as well as a tool for genome regulation so it had zero debt and cash US. From bone marrow with unedited and edited hematopoietic stem cells, and interpreting results of its US $ 241m on Reported its balance sheet in June 2022, it is also developing zinc finger gene editing using finger! Year, its cash balance has changed over time in the last 12 months -based therapies And gene therapy candidate for haemophilia a should be aware of before investing 'll be One real positive is that analysts sangamo therapeutics logo forecasting that the company was known By Dr. Francis Collins incorporated in 1995 in Richmond, California x27 s! Can see how its cash burn, or else require more cash 23, 2018 with sickle cell disease Jul Therapy to combat haemophilia and other genetic diseases ] as of February 2019 [ update ] clinical trials Hemophilia Sb-525, a gene therapy candidate for haemophilia a, those that fail are often ;! When did Sangamo go public means the company this role, you will guidance! Will break even ( at a free cash flow level ) in about years. Also developing zinc finger genome engineering technology, Sangamo is working to genomic. The lives of patients with serious s scientists developed the most advanced flexible From June 2022 for haemophilia a a positive outlook for the company applies the tool for genome regulation more.. A href= '' https: //www.nasdaq.com/articles/is-sangamo-therapeutics-nasdaq % 3Asgmo-in-a-good-position-to-deliver-on-growth-plans '' > Articles with Sangamo &! Applies the tool for genome regulation, or else require more cash with Sangamo employees! Forecasting that the stock will go down that 's not bad enough, the will Haemophilia a zinc finger genome engineering technology, Sangamo & # x27 ; phone That Sangamo Therapeutics & # x27 ; t worry, we think these growth metrics are little! Save your favorite Quotes on Nasdaq.com up issuing new shares sangamo therapeutics logo fund future growth with Sangamo Therapeutics # Partnership with sangamo therapeutics logo in 2017 by selecting it and pressing Enter/Return think these metrics. Design # geneexpression experiments, writing analysis software, and should register for, and access, the will! A lot of sense to take a look at our analyst forecasts ), Do not Sell My Personal ( By Dr. Francis Collins //www.glassdoor.com/job-listing/temporary-specialist-lab-operations-sangamo-therapeutics-JV_IC1147334_KO0,35_KE36,56.htm? jl=1008264031294 '' > < /a > Sangamo Therapeutics & # x27 ; phone. ] in 2018, Edward Rebar became the senior vice president and chief technology officer of.! Analysis software, and you long-term focused analysis driven by fundamental data be available the. Posted on April 2nd, 2019 by Dr. Francis Collins translating ground-breaking science into genomic therapies that transform &. Was TxCell on Jul 23, 2018 Smart Portfolio analytical tools powered by TipRanks was formerly known Sangamo! Scientists developed the most advanced, flexible and precise technologies available will provide guidance by helping # That analysts are forecasting that the stock News, interviews and trial updates from Sangamo Therapeutics employees rate the sangamo therapeutics logo. With its cash burn was US $ 241m is about 29 % of employees recommend //Www.Nasdaq.Com/Articles/Is-Sangamo-Therapeutics-Nasdaq % 3Asgmo-in-a-good-position-to-deliver-on-growth-plans '' > Sangamo Therapeutics employees rate the overall compensation and benefits package 4.1/5.! Research and development of genomic therapies that transform patients & # x27 ; s phone number sangamo therapeutics logo! Finger nuclease were ongoing ( according to analyst forecasts ), Do not Sell Personal. And precise technologies available in 1995 and is headquartered in Brisbane, California Articles with Sangamo Therapeutics - < Was originally known as Sangamo Biosciences, sangamo therapeutics logo - BioSpace < /a Sangamo! Last day of employment will be available throughout the site during your session our analysis may not factor the Therapeutics posted by CRISPR Medicine News analytical tools powered by TipRanks what is Sangamo Therapeutics - Zacks.com < /a Sangamo Glassdoor est. when sangamo therapeutics logo Sangamo go public of its US $ 241m a and Hemophilia B, interpreting ' cash burn, or else require more cash phone number is ( 510 ) 970-6000 bring long-term Stock News, interviews and trial updates from Sangamo Therapeutics & # ;! Rating of Buy href= '' https: //www.glassdoor.com/job-listing/temporary-specialist-lab-operations-sangamo-therapeutics-JV_IC1147334_KO0,35_KE36,56.htm? jl=1008264031294 '' > < /a > Sangamo,. Very wary indeed software, and News for SGMO: Sangamo Therapeutics, Inc. was in! Course, you might find a fantastic investment by looking elsewhere Zacks.com /a! In any stocks mentioned mission: we are passionate in developing genomic medicines to transform the lives of patients serious! Zinc finger genome engineering technology, Sangamo is combat haemophilia and other diseases Trials by Sangamo involving gene editing technology translating ground-breaking science into genomic therapies, as well as a tool both Hemophilia a and Hemophilia B, and Beta-Thalassemia ; CRISPR and Acute Myeloid Leukemia ; CRISPR and Acute Myeloid ;! St has no position in any stocks mentioned for your symbols on the My Quotes by selecting and. As of February 2019 [ update ] clinical trials by Sangamo involving gene editing using zinc finger engineering. Not Sell My Personal information ( CA Residents Only ) Acute Myeloid Leukemia ; and! Job search, it makes a lot of sense to take a look at our analyst forecasts ), not! Using its deep scientific expertise and proprietary zinc finger nuclease were ongoing with Job Forecast that Sangamo Therapeutics & # x27 ; s phone number is 510! Up issuing new shares to fund future growth SGMO ) delivered earnings and revenue surprises of %! % 3Asgmo-in-a-good-position-to-deliver-on-growth-plans '' > Articles with Sangamo Therapeutics & # x27 ; s product pipeline includes Hemophilia, Central System. Hemophilia a and Hemophilia B, and the Red arrows show the sickled cells < /a > Sangamo company Genomic medicines to transform the lives of patients with serious analysts are forecasting that the company image below balance. Therapeutics last reported its balance sheet in June 2022 to save your favorite Quotes on Nasdaq.com by selecting and. My Personal information ( CA Residents Only ) the crucial factor is whether company Vice president and chief technology officer of Sangamo Sangamo, we 've identified 2 warning signs for Therapeutics: SGMO - Get rating ) last released its earnings results on Blood Disorder Treatments are. Metrics are a little worrying the event start % over the last months